logo
Integrated Aesthetics Now Offers Drug-Free Mental Health Treatment, Exomind

Integrated Aesthetics Now Offers Drug-Free Mental Health Treatment, Exomind

Spring, TX— Integrated Aesthetics, a comprehensive aesthetics and wellness practice, has expanded its whole-person care model with the introduction of EXOMIND, an FDA-cleared, drug-free therapy for Major Depressive Disorder (MDD). The non-invasive protocol employs EXOMIND's patented ExoTMS™ technology to stimulate specific neural circuits in the brain responsible for emotional regulation, cognitive control, and decision-making. EXOMIND helps patients regain mental clarity, resilience, and balanced mood in under 30 minutes per session.
Located in Spring and The Woodlands, Texas, Integrated Aesthetics has long combined plastic surgery expertise, advanced dermatologic services, and a 60-plus-treatment medspa under one roof. By adding EXOMIND to its wellness portfolio, the practice aims to give patients a safe, comfortable route to clearer thinking and balanced mood—no pharmaceuticals, injections, or anesthesia required.
'Beauty and confidence flourish when the mind is healthy,' said board-certified plastic surgeon Dr. Young Cho. 'Our patients already trust us to care for their bodies and their skin; EXOMIND now lets us support their mental wellness without medication, downtime, or stigma. It's a natural extension of our mission to treat the whole person.
EXOMIND addresses a growing public-health priority: mental wellness now ranks as the number-one health concern among U.S. adults, outranking both obesity and cancer. Recognizing this urgent need, Integrated Aesthetics takes a holistic approach that pairs leading-edge aesthetic services with science-backed cognitive treatments.
The EXOMIND device targets the brain with focused magnetic pulses, promoting neuroplasticity, rebuilding weakened neural pathways, and 're-training' thought patterns linked to depression. Reported benefits include sharper mental clarity, relief from brain fog, improved emotional stability, assistance in addiction recovery, reduced anxiety, and even metabolic support for weight-management efforts—all without systemic side effects.
Integrated Aesthetics' multidisciplinary team guides each patient through a comprehensive consultation to determine candidacy. Six sessions (two per week) complete the protocol, each lasting less than half an hour, so patients can resume their day immediately. Most describe the sensation as a gentle tapping on the scalp—comfortable and entirely non-claustrophobic.
The new service aligns perfectly with the practice's broader wellness offerings, which include hormone optimization, sexual health therapies, body composition programs, and regenerative treatments. The practice's co-founder and board-certified dermatologist, Dr. Melissa Chiang, explained, 'Exomind helps quiet the negative self-talk and judgment that so many of us struggle with—the very patterns that often bring people into our practice in the first place. We've always focused on helping you feel confident in your outer beauty—but with Exomind, we now have the opportunity to help you see the beauty within yourself as well.'
For individuals who have not responded to—or prefer to avoid—pharmaceutical antidepressants, EXOMIND offers an attractive alternative. Unlike medications that can require weeks to titrate and may cause weight change, sexual side effects, or systemic fatigue, the ExoTMS approach delivers targeted neuromodulation while patients remain fully alert. After completing the full six-session course, many report lasting improvements that continue to strengthen over subsequent weeks as neural networks adapt.
Integrated Aesthetics invites adults experiencing depression, persistent anxiety, brain fog, or other mood-related concerns to schedule an EXOMIND consultation at either of its convenient locations. The Spring office is located at 5061 Farm to Market 2920, Spring, TX 77388, and the Woodlands location is at 26118 I-45, Spring, TX 77386. For appointments or additional information, call (281) 404-5454 or visit https://www.integratedaesthetics.com/.
Founded by Dr. Young Cho and Dr. Melissa Chiang, Integrated Aesthetics delivers plastic surgery, dermatology, medspa, and wellness solutions in a single concierge setting. The practice's evidence-driven, patient-centered approach encompasses surgical expertise, minimally invasive aesthetic and wellness treatments, regenerative medicine, and now EXOMIND neuromodulation—empowering clients to pursue lasting confidence and holistic vitality at every life stage.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TMO Receives FDA Approval for Oncomine Dx Target Test
TMO Receives FDA Approval for Oncomine Dx Target Test

Yahoo

time6 hours ago

  • Yahoo

TMO Receives FDA Approval for Oncomine Dx Target Test

Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers
FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers

Epoch Times

time6 hours ago

  • Epoch Times

FDA Advises Americans Against ‘Mousse' Sunscreens, Warns 5 Manufacturers

Americans should 'beware' of sunscreen products in mousse form as they may not be effective, the Food and Drug Administration (FDA) said in an Aug. 12 X post, with the agency sending warning letters to five companies marketing sunscreen products. The letters were sent on Aug. 6 to Texas-based Supergoop, Pennsylvania-based Fallien Cosmeceuticals Ltd., Israel-based K & Care Organics, Sweden-based Kalani AB, and Florida-based Vacation Inc.

Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)

Yahoo

time11 hours ago

  • Yahoo

Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)

Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01). A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year. Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway. Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need. While we acknowledge the potential of RADX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store